S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
S&P 500   3,841.94
DOW   31,496.30
QQQ   308.68
Log in

Intersect ENT Stock Forecast, Price & News

+0.87 (+3.79 %)
(As of 03/5/2021 12:00 AM ET)
Today's Range
Now: $23.82
50-Day Range
MA: $24.28
52-Week Range
Now: $23.82
Volume256,261 shs
Average Volume206,660 shs
Market Capitalization$779.37 million
P/E RatioN/A
Dividend YieldN/A
Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It also provides SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.
Intersect ENT logo


Is XENT A Good Stock To Buy Now?
December 16, 2020 |  finance.yahoo.com
Intersect ENT: Q3 Earnings Insights
November 2, 2020 |  finance.yahoo.com
Intersect ENT provides preliminary Q3 figures
October 15, 2020 |  seekingalpha.com
See More Headlines

Industry, Sector and Symbol

Industry Surgical & medical instruments
Current SymbolNASDAQ:XENT
Year FoundedN/A



Sales & Book Value

Annual Sales$109.14 million
Book Value$3.75 per share


Net Income$-42,990,000.00


Market Cap$779.37 million
Next Earnings Date3/9/2021 (Confirmed)


Overall MarketRank

1.24 out of 5 stars

Medical Sector

839th out of 1,972 stocks

Surgical & Medical Instruments Industry

89th out of 169 stocks

Analyst Opinion: 1.1Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.6 5 -4 -3 -2 -1 -
+0.87 (+3.79 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive XENT News and Ratings via Email

Sign-up to receive the latest news and ratings for XENT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Intersect ENT (NASDAQ:XENT) Frequently Asked Questions

Is Intersect ENT a buy right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Intersect ENT in the last year. There are currently 1 sell rating, 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Intersect ENT stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in XENT, but not buy additional shares or sell existing shares.
View analyst ratings for Intersect ENT
or view top-rated stocks.

What stocks does MarketBeat like better than Intersect ENT?

Wall Street analysts have given Intersect ENT a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Intersect ENT wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Intersect ENT's next earnings date?

Intersect ENT is scheduled to release its next quarterly earnings announcement on Tuesday, March 9th 2021.
View our earnings forecast for Intersect ENT

How can I listen to Intersect ENT's earnings call?

Intersect ENT will be holding an earnings conference call on Tuesday, March 9th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Intersect ENT's earnings last quarter?

Intersect ENT, Inc. (NASDAQ:XENT) released its quarterly earnings data on Thursday, November, 5th. The medical equipment provider reported ($0.34) EPS for the quarter, topping the consensus estimate of ($0.44) by $0.10. The medical equipment provider earned $22.72 million during the quarter, compared to analyst estimates of $21.78 million. Intersect ENT had a negative trailing twelve-month return on equity of 55.81% and a negative net margin of 71.96%. Intersect ENT's quarterly revenue was down 5.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted ($0.41) earnings per share.
View Intersect ENT's earnings history

How has Intersect ENT's stock price been impacted by COVID-19 (Coronavirus)?

Intersect ENT's stock was trading at $21.50 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, XENT stock has increased by 10.8% and is now trading at $23.82.
View which stocks have been most impacted by COVID-19

What guidance has Intersect ENT issued on next quarter's earnings?

Intersect ENT updated its fourth quarter 2020 Pre-Market earnings guidance on Tuesday, January, 12th. The company provided EPS guidance of for the period. The company issued revenue guidance of $27.7-28.1 million, compared to the consensus revenue estimate of $27.67 million.

What price target have analysts set for XENT?

8 brokers have issued 12-month price objectives for Intersect ENT's shares. Their forecasts range from $10.00 to $32.00. On average, they anticipate Intersect ENT's stock price to reach $23.00 in the next year. This suggests that the stock has a possible downside of 3.4%.
View analysts' price targets for Intersect ENT
or view top-rated stocks among Wall Street analysts.

Who are Intersect ENT's key executives?

Intersect ENT's management team includes the following people:
  • Mr. Thomas A. West, Pres, CEO & Director (Age 57, Pay $435.89k)
  • Mr. Richard A. Meier, Exec. VP & CFO (Age 61, Pay $182.88k)
  • Ms. Christine R. Kowalski, Exec. VP & COO (Age 63)
  • Mr. Patrick A. Broderick, Exec. VP, Gen. Counsel & Corp. Sec. (Age 62)
  • Ms. Reyna M. Fernandez, Chief Human Resource Officer
  • Mr. Drake R. Parker, Advisor of Strategic Initiatives (Age 57)

What is Thomas West's approval rating as Intersect ENT's CEO?

7 employees have rated Intersect ENT CEO Thomas West on Glassdoor.com. Thomas West has an approval rating of 41% among Intersect ENT's employees. This puts Thomas West in the bottom 10% of approval ratings compared to other CEOs of publicly-traded companies.

Who are some of Intersect ENT's key competitors?

What other stocks do shareholders of Intersect ENT own?

What is Intersect ENT's stock symbol?

Intersect ENT trades on the NASDAQ under the ticker symbol "XENT."

Who are Intersect ENT's major shareholders?

Intersect ENT's stock is owned by many different institutional and retail investors. Top institutional investors include Artisan Partners Limited Partnership (9.07%), BlackRock Inc. (8.82%), Jennison Associates LLC (3.19%), Nuveen Asset Management LLC (2.17%), Northern Trust Corp (1.28%) and JPMorgan Chase & Co. (1.04%). Company insiders that own Intersect ENT stock include David Aaron Lehman, Jeryl L Hilleman, Lisa D Earnhardt, Richard A Meier, Robert H Binney, Jr, Susan P Stimson and Thomas A West.
View institutional ownership trends for Intersect ENT

Which major investors are selling Intersect ENT stock?

XENT stock was sold by a variety of institutional investors in the last quarter, including Assenagon Asset Management S.A., JPMorgan Chase & Co., Voloridge Investment Management LLC, Northern Trust Corp, Gabelli Funds LLC, Great Lakes Advisors LLC, Russell Investments Group Ltd., and State of Wisconsin Investment Board.
View insider buying and selling activity for Intersect ENT
or view top insider-selling stocks.

Which major investors are buying Intersect ENT stock?

XENT stock was purchased by a variety of institutional investors in the last quarter, including Artisan Partners Limited Partnership, BlackRock Inc., Morgan Stanley, Nuveen Asset Management LLC, Jennison Associates LLC, Gyon Technologies Capital Management LP, HighTower Advisors LLC, and Renaissance Technologies LLC. Company insiders that have bought Intersect ENT stock in the last two years include Richard A Meier, and Thomas A West.
View insider buying and selling activity for Intersect ENT
or or view top insider-buying stocks.

How do I buy shares of Intersect ENT?

Shares of XENT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Intersect ENT's stock price today?

One share of XENT stock can currently be purchased for approximately $23.82.

How much money does Intersect ENT make?

Intersect ENT has a market capitalization of $779.37 million and generates $109.14 million in revenue each year. The medical equipment provider earns $-42,990,000.00 in net income (profit) each year or ($1.37) on an earnings per share basis.

How many employees does Intersect ENT have?

Intersect ENT employs 402 workers across the globe.

What is Intersect ENT's official website?

The official website for Intersect ENT is www.intersectent.com.

Where are Intersect ENT's headquarters?

Intersect ENT is headquartered at 1555 ADAMS DRIVE, MENLO PARK CA, 94025.

How can I contact Intersect ENT?

Intersect ENT's mailing address is 1555 ADAMS DRIVE, MENLO PARK CA, 94025. The medical equipment provider can be reached via phone at 650-641-2100 or via email at [email protected]

This page was last updated on 3/6/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.